Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
First Wave BioPharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
FWBI
Nasdaq
8731
https://www.firstwavebio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for First Wave BioPharma Inc
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
- Mar 18th, 2024 11:00 am
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
- Mar 14th, 2024 10:00 am
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
- Mar 5th, 2024 12:00 pm
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
- Mar 4th, 2024 1:00 pm
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
- Feb 13th, 2024 12:00 pm
First Wave BioPharma to Present at the DealFlow MicroCap Conference
- Jan 23rd, 2024 12:00 pm
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
- Jan 17th, 2024 12:00 pm
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
- Jan 4th, 2024 11:00 am
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
- Dec 27th, 2023 4:55 pm
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
- Dec 27th, 2023 11:00 am
First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company
- Dec 18th, 2023 11:00 am
First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders
- Dec 14th, 2023 2:15 pm
First Wave BioPharma to Participate in BIO Partnering @JPM During “J.P. Morgan Week 2024”
- Dec 6th, 2023 12:00 pm
First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference
- Dec 5th, 2023 12:00 pm
Date and Time Announced for First Wave BioPharma CEO James Sapirstein’s Presentation at the 2023 BIO Investor Forum
- Oct 10th, 2023 11:00 am
First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference
- Oct 3rd, 2023 11:00 am
First Wave BioPharma To Present at the BIO Investor Forum
- Sep 15th, 2023 12:45 pm
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market
- Sep 14th, 2023 2:43 pm
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
- Sep 14th, 2023 10:00 am
First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 5th, 2023 11:00 am
Scroll